

	Year	Provider	User	Research Description
1	2014	Aberystwyth University	University of Buea	An Aberystwyth University researcher will provide a University of Buea researcher with inhibitors that had previously been shown to be active against <i>Fasciola</i> . The University of Buea researcher will screen these inhibitors against <i>Onchocerca</i> microfilariae and macrofilariae.
2	2013	Alnylam	Aberystwyth University	Alnylam will design an optimized set of siRNAs for an Aberystwyth University researcher to use in his schistosomiasis studies. Alnylam will also provide the researcher with lipophilic <i>in vivo</i> siRNA delivery reagents, which the researcher will use to examine the effect of gene knockdown on schistosomes.
3	2014	Alnylam	Northeastern University, NII	Alnylam will design and synthesize optimized siRNAs for an NII researcher to assess regulation of host hepatocyte genes during liver-stage malaria. A Northeastern University researcher will encapsulate the siRNAs for targeted delivery to hepatocytes.
4	2014	Alnylam	Tulane University	Alnylam will design, for a Tulane University researcher, a set of optimized siRNAs against a host protein expressed in macrophages during infection. The researcher will assess the effect that knockdown of this protein will have on <i>M. tuberculosis</i> infection <i>in vitro</i> and in a non-human primate model of infection.
5	2016	Alnylam	SCRI	Alnylam will provide an SCRI researcher with a set of siRNAs targeting a hepatocyte receptor. The siRNAs will be used to assess the result of knocking down the receptor on <i>P. falciparum</i> invasion of hepatocytes <i>in vivo</i> .
6	2017	Alnylam	Fiocruz	Alnylam will design and synthesize optimized siRNAs for a Fiocruz researcher to conduct gene validation studies via RNAi in his drug discovery efforts against <i>S. mansoni</i> .
7	2012	AstraZeneca	Anacor	AstraZeneca will provide Anacor researchers with knowledge, data, and structures of inhibitors to inform and support the researchers' development of products for <i>Shigella</i> .
8	2012	AstraZeneca	Anacor	AstraZeneca will screen Anacor's boron-based compounds against <i>M. tuberculosis</i> drug targets identified by AstraZeneca.
9	2012	AstraZeneca	iThemba	AstraZeneca will provide iThemba researchers with computational and predictive chemistry know-how and support to improve compound characteristics for the researchers' tuberculosis drug candidates.
10	2012	AstraZeneca	LSTM	AstraZeneca will provide an LSTM researcher with sets of advanced preclinical and clinical compounds to screen against malaria parasites. AstraZeneca will also provide the preclinical information package of any promising hits identified by the researcher to help advance the hits to <i>in vivo</i> studies.
11	2012	AstraZeneca	UCSF	AstraZeneca will provide UCSF researchers with a cysteine protease inhibitor compound library to screen against kinetoplastids, malaria parasites, schistosomes, and hookworms.
12	2012	AstraZeneca	University of Dundee	AstraZeneca will provide a University of Dundee researcher with a GSK-3 inhibitor compound library to screen against kinetoplastids.
13	2013	AstraZeneca	LSTM	AstraZeneca will provide an LSTM researcher with access to its high-throughput screening facility to test AstraZeneca compounds against the essential <i>Wolbachia</i> bacteria found in the parasites that cause onchocerciasis and lymphatic filariasis.
14	2013	AstraZeneca	McGill University	AstraZeneca will provide McGill University researchers with its compounds that were promising in DNDI's phenotypic anti-helminth screen. The researchers will screen the compounds against wildtype and mutant <i>C. elegans</i> strains to elucidate the compounds' mechanisms of action.
15	2013	AstraZeneca	McGill University	AstraZeneca will provide McGill University researchers with approximately 10,000 diverse compounds to screen against <i>C. elegans</i> . Data from the screen was included in a Wellcome Trust grant application, which passed the grant's preliminary round.
16	2013	AstraZeneca	Northeastern University	AstraZeneca will perform ADME assays on inhibitors of <i>Plasmodium</i> and <i>T. brucei</i> that were identified by a Northeastern University researcher.
17	2013	AstraZeneca	Stanford University	AstraZeneca will provide a Stanford University researcher with technical know-how to enable formulation of a peptide with activity against cutaneous leishmaniasis.
18	2013	AstraZeneca	Swiss TPH	AstraZeneca will provide a Swiss TPH researcher with compounds, including a compound in clinical trials against <i>M. tuberculosis</i> , to screen against <i>M. ulcerans</i> .
19	2013	AstraZeneca	UCSF	AstraZeneca will provide UCSF researchers with non-azole CYP51 inhibitors and a diverse set of compounds to screen against <i>T. cruzi</i> and <i>Leishmania</i> .
20	2015	BRI	UCAD	A BRI researcher will express and purify a recombinant <i>Schistosoma</i> protein for a UCAD researcher who will assess the <i>in vitro</i> immune response to this protein in human cells.
21	2016	BRI	NIMR	A BRI researcher provided an NIMR researcher with genomic DNA from <i>S. mansoni</i> and the parasite's intermediate snail host, <i>B. pfeifferi</i> . The NIMR researcher will use the DNA as positive controls during her characterization of snails and <i>S. mansoni</i> in Nigeria.
22	2014	CPC	Stanford University	CPC will provide a Stanford University researcher with approximately 250 samples from non-malarious febrile patients from Cameroon. The Stanford researcher will use the samples to design a fever multiplex diagnostic best suited for Cameroon.
23	2016	CPC	NIMR	A NIMR researcher will provide a CPC researcher with a set of natural product extracts. The CPC researcher will screen the extracts against <i>Plasmodium</i> parasites <i>in vitro</i> .
24	2013	Eisai	IDRI	Eisai will provide an IDRI researcher with advice regarding parameters to consider during adjuvant design.
25	2013	Eisai	University of Dundee	Eisai will provide a University of Dundee researcher with a compound to screen against malaria parasites.
26	2013	Eisai	University of Dundee	Eisai will provide a University of Dundee researcher with an additional two compounds to screen against malaria parasites.

27	2013	Eisai	Northeastern University	Eisai will provide a Northeastern University researcher with SAR expertise and advice to facilitate the researcher's design of phosphodiesterase inhibitors against <i>T. brucei</i> .
28	2014	Eisai	LSTM	Eisai will provide an LSTM researcher with inhibitors to test against cerebral malaria.
29	2015	Eisai	UC San Diego	Eisai will provide UC San Diego researchers with an inhibitor to test against <i>Leishmania</i> and <i>T. cruzi</i> , either alone or in combination with other inhibitors.
30	2015	Eisai	UC San Diego	Eisai will provide a UC San Diego researcher with inhibitors to screen against <i>Leishmania</i> , <i>T. cruzi</i> , <i>S. mansoni</i> , and <i>Brugia</i> .
31	2017	Eisai	UC San Diego	Eisai will provide UC San Diego researchers with two targeted sets of inhibitors to screen against <i>S. mansoni</i> .
32	2017	Eisai	UC San Diego, Northeastern University	Eisai will provide UC San Diego and Northeastern University researchers with a targeted set of inhibitors and their structures to test against <i>Leishmania spp.</i> and <i>T. cruzi</i> .
33	2018	Eisai	IDRI	Eisai will provide IDRI investigators with selected phosphodiesterase (PDE) V inhibitors and calcium channel blockers. The investigators will use IDRI's high-content imaging system to screen the compounds for activity against intracellular <i>M. tuberculosis</i> to identify candidates for further drug development.
34	2018	Eisai	IDRI	Eisai will provide IDRI investigators with a peroxisome proliferator-activated receptor (PPAR) agonist. Investigators at IDRI will screen the PPAR agonist against intracellular <i>L. donovani</i> in the hopes of identifying new candidate therapeutics against leishmaniasis.
35	2018	Eisai	University of Buea	Eisai will provide University of Buea investigators with several classes of inhibitors including kinase inhibitors and calcium channel blockers. The investigators will screen the compounds for activity against <i>Onchocerca</i> adult worms to identify candidates for further drug development.
36	2019	Eisai	UTSW	Eisai will provide UTSW investigators with a class of inhibitors that may have antileishmanial activity. The investigators will screen the compounds for leishmaniasis drug discovery.
37	2019	Eisai	University of Yaoundé I	Eisai will provide University of Yaoundé I investigators with dihydrofolate reductase (DHFR) inhibitors and potassium channel blockers. The investigators will screen the compounds for human African trypanosomiasis (HAT), leishmaniasis and malaria drug discovery.
38	2014	Emory University	Kineta	An Emory University researcher will provide Kineta with <i>in vivo</i> data. The Emory University researcher will license a virus strain and provide its animal model set up guidance.
39	2014	Emory University	WRAIR, GSK	Emory University scientists will collaborate with scientists from WRAIR to measure the plasmablast response induced in human subjects following administration of two candidate dengue vaccines. Researchers will first vaccinate with a live-attenuated dengue vaccine and then "boost" with a purified inactivated dengue vaccine. WRAIR and GSK co-developed both of these candidate vaccines.
40	2014	Emory University, CDC	Caltech	An Emory University researcher will provide a Caltech researcher with advice regarding the development of a polio diagnostic. A CDC researcher will provide information about primers to use for this diagnostic.
41	2017	FIND	Institut Pasteur Korea	Institut Pasteur Korea is developing new drugs against multidrug-resistant TB (MDR-TB). Selected compounds showed promise <i>in vivo</i> , and Institut Pasteur Korea was interested in screening them against additional drug resistant strains to inform the selection of a preclinical candidate. BVGH connected Institut Pasteur Korea with FIND, who agreed to share resistant TB strains to support drug development efforts.
42	2020	Fiocruz	GIBH	A Fiocruz researcher will test the activity of a leprosy drug candidate developed by a GIBH investigator against <i>M. leprae</i> strains from Brazilian patients.
43	2013	GRIDD	AstraZeneca	GRIDD will provide AstraZeneca Bangalore researchers with samples from its Nature Bank to screen against <i>M. tuberculosis</i> .
44	2014	GRIDD	Swiss TPH	GRIDD will provide a Swiss TPH researcher with samples from its Nature Bank to screen against helminths and schistosomes.
45	2018	GRIDD	University of Ibadan	A researcher from GRIDD will perform activity-guided fractionation on natural product extracts previously demonstrated by a University of Ibadan researcher to have activity against <i>S. mansoni</i> and <i>S. haematobium</i> or their intermediate snail hosts.
46	2012	GSK	CWHM	GSK will provide CWHM researchers with information, data, and insights into the development of MetAp-1 inhibitors for tuberculosis.
47	2012	GSK	UW	GSK will work collaboratively with a UW researcher to identify the lead compound in a series, originally from the TCAMS.
48	2012	GSK	UW	A UW researcher will provide GSK with confidential information and compounds. GSK will assess the compounds' ability to block malaria parasite transmission.
49	2013	GSK	NII	GSK will provide an NII researcher with kinase inhibitors to study various molecular pathways in blood-stage malaria parasites.
50	2013	GSK	NII	GSK will provide an NII researcher with kinase inhibitors to study <i>M. tuberculosis</i> metabolic pathways.
51	2013	GSK	UCSF	GSK will provide a UCSF researcher with two targeted sets of compounds to screen against schistosomal worms.
52	2014	GSK	IDRI	GSK will provide an IDRI researcher with a targeted set of inhibitors to screen against <i>M. tuberculosis</i> .
53	2014	GSK	MIT	GSK will provide an MIT researcher with compounds to assess a technical issue in a liver-stage malaria model.
54	2014	GSK	NII	GSK will provide an NII researcher with a set of kinase inhibitors to screen against liver-stage malaria parasites.
55	2014	GSK	SCRI	GSK will provide an SCRI researcher with a small collection of inhibitors to screen against <i>T. brucei</i> .
56	2015	GSK	Fiocruz	GSK will provide a Fiocruz researcher with a targeted set of compounds from its TCAKS to assess their effects on <i>T. cruzi</i> .

57	2015	GSK	UBC	GSK will provide a UBC researcher with a set of compounds with different anti-malarial properties and clearance times. The UBC researcher will test the compounds' effects on erythrocyte deformability during <i>Plasmodium</i> infection.
58	2015	GSK	UC San Diego	GSK will provide a UC San Diego researcher with a targeted set of compounds to screen against <i>T. cruzi</i> and <i>Leishmania</i> .
59	2017	GSK	UCB	GSK will provide a UCB researcher with a set of small molecules that were previously demonstrated to have promising activity against <i>M. tuberculosis</i> -infected macrophages <i>in vitro</i> . The UCB researcher will use his novel assays to assess whether the molecules' anti-tubercular activities are due to activation of the host macrophages' autophagy pathway.
60	2018	GSK	UCSF	GSK will provide a UCSF researcher with a targeted set of compounds to screen for activity against <i>P. falciparum</i> .
61	2019	GSK	WUSTL	GSK will provide WUSTL investigators with its TCAMS compound library to screen for antimalarial drug discovery.
62	2013	IDRI	SAMRC	IDRI will provide SAMRC and University of Cape Town researchers with expertise and advice to improve the solubility and bioavailability of the researchers' anti-tuberculosis compounds.
63	2018	IDRI	Institut Pasteur de Tunis, NII	An IDRI researcher will evaluate the <i>in vivo</i> efficacy of PPM antigens co-developed by Institut Pasteur de Tunis and NII investigators as a post-exposure tuberculosis vaccine candidate.
64	2020	Institut Pasteur Korea	University of Zambia	Institut Pasteur Korea will test the bactericidal activity of compounds synthesized and derived from natural sources by an investigator from University of Zambia to identify promising leads for tuberculosis drug discovery.
65	2016	J&J	Swiss TPH	J&J will provide a Swiss TPH researcher with a targeted set of small molecule receptor agonists to screen against hookworms <i>in vitro</i> .
66	2016	J&J	WEHI	J&J will provide WEHI researchers with its Jump-stARter library to screen against <i>P. falciparum in vitro</i> .
67	2017	J&J	IDRI	J&J will provide IDRI researchers with its Jump-stARter library to screen against intracellular <i>M. tuberculosis</i> and <i>Leishmania</i> parasites. The researchers will use IDRI's high-content imaging system to perform the screens.
68	2017	J&J	NIH	J&J will provide NIH researchers with its Jump-stARter library to screen against <i>M. tuberculosis in vitro</i> under conditions that mimic important aspects of human pathogenesis.
69	2017	J&J	U of T	J&J will provide a U of T researcher with its Jump-stARter library. The researcher will screen the library against <i>C. elegans</i> to identify inhibitors of a unique metabolic pathway found in parasitic worms.
70	2017	J&J	WUSTL	J&J will provide a WUSTL researcher with its Jump-stARter library to screen against a <i>M. tuberculosis</i> enzyme demonstrated to be essential for the growth and virulence of the bacterium.
71	2018	J&J	U of T	J&J will provide an investigator from the U of T with its Jump-stARter library to screen in a <i>C. elegans</i> model of soil-transmitted helminths. The investigator will employ his novel assay to identify molecules that target helminths under variable host conditions.
72	2018	J&J	University of Yaoundé I	An investigator at the University of Yaoundé I, Cameroon is working to identify hit inhibitors of critical parasitic metabolic pathways to develop high-need drugs against human African trypanosomiasis (HAT), leishmaniasis, and malaria. To support these efforts, J&J's computer-aided design team conducted analysis to select the best compounds for this collaboration and will be sharing the selected compounds with the University of Yaoundé I investigator.
73	2018	J&J	WUSTL	J&J will provide WUSTL investigators with its Jump-stARter library to screen for antimalarial drug discovery.
74	2019	J&J	UC San Diego	J&J will provide UC San Diego investigators with a phenotypic compound library to screen for schistosomiasis drug discovery.
75	2019	J&J	UDUS	J&J will provide a UDUS investigator with a phenotypic screening library to screen for antimalarial drug discovery.
76	2019	J&J	University of Melbourne	J&J will provide University of Melbourne investigators with its Jump-stARter library for screening in anthelmintic drug discovery.
77	2020	J&J	LSTM	Johnson & Johnson is sharing diverse and targeted compounds with Professor Nick Casewell at the Liverpool School of Tropical Medicine (LSTM) to develop novel treatments for Snakebites.
78	2020	J&J	SCRI, University of Washington	J&J will provide its Jump-stARter library to SCRI investigator Dr. Peter Myler to screen for leishmaniasis drug discovery. Under the umbrella of SSGCID, SCRI will partner with the University of Washington's Dr. Wes Van Voorhis to carry out screening of the library.
79	2012	KCCR	Stanford University	A KCCR researcher will provide Stanford University researchers with stool samples to support the researchers' helminth diagnostic product development and testing.
80	2013	KCCR	Northeastern University	KCCR and Northeastern University researchers will explore grant opportunities together, develop exchange between students, and conduct collaborative lab projects.
81	2013	KU	Eisai	KU will provide Eisai researchers with expertise and ideas to address formulation challenges of Eisai's anti-fungal compound.
82	2014	KU	Kineta	KU will develop formulations of Kineta's antiviral.
83	2014	McGill University	UBC	A McGill University researcher will provide a UBC researcher with frozen cell extracts of <i>Cryptosporidium</i> infected cells. The UBC researcher will use these extracts to identify potential antigens for use in a vaccine.
84	2014	McGill University	UBC	A McGill University researcher will provide a UBC researcher with frozen cell extracts of <i>T. cruzi</i> infected cells. The UBC researcher will use these extracts to identify potential antigens for use in a vaccine.
85	2015	McMaster University	PATH	PATH and a researcher from McMaster University will co-develop a microfluidic diagnostic to detect bacteria in banked milk.

86	2015	Merck KGaA*	University of Buea	Merck KGaA, Darmstadt, Germany, will provide a University of Buea researcher with a subset of highly potent Hsp90 inhibitors to screen against <i>Onchocerca</i> worms, and identify compounds that selectively kill both microfilariae and adult <i>O. volvulus</i> , without adverse effects to <i>Loa loa</i> microfilariae.
87	2017	Merck KGaA*	UC San Diego	Merck KGaA, Darmstadt, Germany, will provide a UC San Diego investigator with a targeted library of phosphoinositide-3-kinase (PI3K) inhibitors. The UC San Diego investigator will screen these inhibitors for activity against the causative agents of Chagas disease, human African trypanosomiasis, and leishmaniasis.
88	2019	Merck KGaA*	University of Yaoundé I	Merck KGaA, Darmstadt, Germany, will be sharing its Mini Library with Professor Fabrice Boyom at the University of Yaoundé I for Buruli ulcer drug discovery.
89	2019	Merck KGaA*	GRIDD	Merck KGaA, Darmstadt, Germany, will provide GRIDD investigator Professor Vicky Avery with its Mini Library to screen for Chagas disease, human African trypanosomiasis (HAT), and leishmaniasis drug discovery.
90	2020	Merck KGaA*	University of Yaoundé I	Merck KGaA, Darmstadt, Germany, will provide University of Yaoundé I investigator Dr. Fabrice Boyom with its Mini-Library – a diverse set of compounds – to screen for leishmaniasis and amoebiasis drug discovery.
91	2021	Merck KGaA*	ABU	Merck KGaA, Darmstadt, Germany, will share its Open Global Health Library with an ABU researcher for schistosomiasis drug discovery.
92	2021	Merck KGaA*	Eijkman Institute for Molecular Biology	Merck KGaA, Darmstadt, Germany, will share its Open Global Health Library with an Eijkman Institute for Molecular Biology researcher for dengue drug discovery.
93	2021	Merck KGaA*	LSTM	Merck KGaA, Darmstadt, Germany, has shared its Open Global Health Library with a LSTM researcher for snakebite drug discovery.
94	2021	Merck KGaA*, Swiss TPH	University of Yaoundé I	With support from Merck KGaA, Darmstadt, Germany, Swiss TPH will screen natural product extracts collected by a University of Yaoundé I researcher for antischistosomal activity.
95	2022	Merck KGaA*, U Bamako	KNUST	With support from Merck KGaA, Darmstadt, Germany, a University of Bamako researcher will screen natural product extracts collected by a KNUST researcher for antimalarial activity.
96	2018	MIT	University of Buea	A MIT researcher will share Ampli Blocks, a set of blocks that provide the platform for diagnostic technology, to support a University of Buea researcher's development of a POC diagnostic device to detect <i>O. volvulus</i> .
97	2018	MIT	University of Ibadan	A MIT researcher will share Ampli Blocks, a set of blocks that provide the platform for diagnostic technology, to support the University of Ibadan researcher's development of a POC diagnostic device to detect <i>S. haematobium</i> .
98	2018	MMV	UCSF	UCSF will provide MMV with lead antimalarial compounds. MMV scientists will assess the solubility and metabolic stability of these compounds through <i>in vitro</i> studies.
99	2013	MSD**	Emory University	MSD will provide an Emory University researcher studying tuberculosis with membrane-bound protein purification expertise.
100	2013	MSD**	UCSF/UC San Diego & SCRI	MSD will provide a UCSF/UC San Diego researcher with HMG-CoA reductase inhibitors (statins) to screen against schistosomal worms. SCRI will attempt to solve the structure of the <i>S. mansoni</i> HMG-CoA reductase.
101	2014	MSD**	WEHI	MSD will provide a WEHI researcher with a targeted set of compounds to screen against <i>Plasmodium</i> .
102	2018	MSD**	GWU	GWU will provide MSD with lead compounds that have anti-tubercular activity. MSD scientists will screen the selected compounds to determine their activity against a specific <i>M. tuberculosis</i> target.
103	2019	MSD**	SCRI/SSGCID	MSD has developed a set of codon-optimized gene constructs in order to support SSGCID's structural elucidation efforts for <i>Schistosoma</i> HMG-CoA reductase, a drug target for schistosomiasis.
104	2012	NIH	Emory University	NIH will provide an Emory University researcher with biology expertise and support for an RNA-dependent RNA polymerase inhibitor of dengue and Rift Valley Fever viruses.
105	2013	NIH	IDRI	NIH will provide IDRI researchers with natural product extracts to screen against <i>M. tuberculosis</i> .
106	2015	NIH	Institut Pasteur Korea	NCI/NIH will provide Institut Pasteur Korea with natural products to test against kinetoplastids.
107	2015	NIH	Institut Pasteur de Tunis	Researchers from Institut Pasteur de Tunis will be utilizing the NIAID/NIH preclinical services program to increase thermostability of Institut Pasteur de Tunis' investigational rabies vaccine.
108	2014	NIPD	University of Ibadan	A NIPD researcher will provide a University of Ibadan researcher with a lateral flow dipstick diagnostic for schistosomiasis. The Ibadan researcher will assess the ability of the diagnostic, which was developed to diagnose <i>S. japonicum</i> infections, to diagnose <i>S. mansoni</i> infections.
109	2016	NIPD	UCAD	A NIPD researcher will sequence the K13 gene of a set of malaria parasites obtained from Senegalese malaria patients by a UCAD researcher. The sequences obtained will inform the researchers of the mutations occurring in that gene and the likelihood of the development of artemisinin resistance.
110	2016	NIPD	University of Ibadan	A University of Ibadan researcher will collaborate with an NIPD researcher to work on serum samples from Nigerian schistosomiasis patients. The NIPD researcher will host a post-doctoral scientist from Nigeria to identify potential <i>S. mansoni</i> and <i>S. haematobium</i> antigens to incorporate into a schistosomiasis rapid diagnostic.
111	2017	NIPD	CPC	An NIPD researcher will sequence the K13 gene of <i>P. falciparum</i> parasites found within malaria patient blood samples obtained by researchers at CPC. The researchers seek to assess the development of artemisinin resistance in <i>Plasmodium</i> parasites circulating in Cameroon, and to compare parasite genotypes with the patients' responses to treatment – specifically parasite clearance.
112	2014	Northeastern University	CWHM, WUSTL	A Northeastern University researcher will share the structures of a class of inhibitors with CWHM researchers. The CWHM researchers will perform virtual docking to determine whether these inhibitors could be promising against <i>M. tuberculosis</i> .

113	2014	Northeastern University	McGill University	A Northeastern University researcher will synthesize an inhibitor previously demonstrated by a McGill University researcher to inhibit malaria parasites. The McGill University researcher will utilize the compound to repeat his <i>in vivo</i> screens.
114	2015	Northeastern University	DNDi	A researcher at Northeastern University provided DNDi with data from compound assays obtained against cutaneous leishmaniasis; based on these data, DNDi is assessing these compounds against a pan-kinetoplastid assay panel and malaria.
115	2013	Novartis	McMaster University	Novartis will provide a McMaster University researcher with a polyclonal anti-dengue antibody.
116	2018	Novartis	PHRI/other institution	Novartis shared a targeted collection of compounds with a researcher to screen for activity against <i>M. abscessus</i> .
117	2019	Novartis	LNBio	Novartis will provide a researcher from LNBio with several compounds to screen for Chagas disease drug discovery.
118	2019	Novartis	NIMR	Novartis shared expertise with NIMR investigators on fractionation techniques for the isolation of the active compound from a natural extract that has shown antimalarial properties.
119	2012	PATH	KCCR	PATH and a KCCR researcher will discuss and plan the co-development of a novel onchocerciasis diagnostic.
120	2014	PATH	Caltech	PATH will provide a Caltech researcher with expertise, publications, and information to facilitate the development of a tuberculosis diagnostic.
121	2014	PATH	University of Calgary	PATH will provide a University of Calgary researcher with its temperature control system for isothermal amplification to apply to a LAMP-based malaria diagnostic that will be field tested in Ethiopia.
122	2015	PATH	CPC	PATH will provide a CPC researcher with its NINA heater. The CPC researcher will assess the NINA heater's compatibility with a LAMP assay developed to detect malaria gametocytes.
123	2013	Pfizer	60P	Pfizer will provide 60P with its investigator's brochure, exploratory data plan, and degradation studies data for a discontinued compound. 60P is hoping to repurpose the drug as a dengue treatment.
124	2013	Pfizer	CWHM	Pfizer will provide CWHM researchers with two compounds to evaluate in a rat diarrhea model.
125	2013	Pfizer	McGill University	Pfizer will provide a McGill University researcher with a JAK inhibitor to screen in a cerebral malaria model.
126	2013	Pfizer	PATH	Pfizer will provide PATH with a drug's investigator's brochure, summary table of the drug's clinical trials, and drug + cholera toxin study information. PATH aims to repurpose the drug to treat diarrheal diseases.
127	2014	Pfizer	PATH, UVM	Pfizer will provide PATH and a UVM researcher with an inhibitor to test in an animal model of diarrhea.
128	2015	Pfizer	SCRI	Pfizer will provide an SCRI researcher with a compound to test against liver-stage malaria.
129	2016	Pfizer	Swiss TPH	Pfizer will provide a Swiss TPH researcher with a set of small molecule receptor agonists to screen against hookworms <i>in vitro</i> .
130	2018	Pfizer	IDRI	Pfizer will provide IDRI investigators with a phosphodiesterase (PDE) inhibitor to screen for tuberculosis drug discovery.
131	2018	Pfizer	WUSTL/GWU	Pfizer provided WUSTL and GWU investigators expertise on the feasibility of transdermal delivery of an identified antimalarial drug candidate.
132	2019	Pfizer	KEMRI	Pfizer has provided KEMRI investigators with several compounds to validate activity against predicted targets. The investigators will screen the compounds for malaria drug discovery.
133	2021	Pfizer	University of Tokyo	Pfizer agrees to provide a University of Tokyo investigator with compounds for screening against certain potential targets in malaria.
134	2021	Pfizer	University of Yaoundé I	Pfizer agrees to provide a University of Yaoundé I investigator with certain potassium channel blockers. The investigator plans to screen the compounds for activity against HAT, leishmaniasis and malaria.
135	2013	Sanofi	CWHM	Sanofi will provide CWHM researchers with two compounds to evaluate in a rat diarrhea model.
136	2019	SSGCID	PHRI	SSGCID will assist investigators from PHRI at Rutgers by solving the crystal structure of patient-derived antibodies against the TB biomarker lipoarabinomannan (LAM), with the goal of modifying the antibody sequences and increasing the sensitivity of a diagnostic assay for tuberculosis.
137	2020	SSGCID	Fiocruz	SSGCID is supporting a Fiocruz researcher's efforts to develop a construct to express <i>T. cruzi</i> Topoisomerase II, a drug target for Chagas disease.
138	2021	SSGCID	IP Montevideo	SSGCID, which is contracted through NIAID (contract HHSN272201700059C), will investigate the crystal structure of targets identified by an IP Montevideo researcher to inform drug design for Chagas disease, HAT, and leishmaniasis.
139	2014	Stanford University	Caltech	A Stanford University researcher will provide a Caltech researcher with DNA and primers to test in a microfluidics instrument.
140	2016	Stanford University	USF	A Stanford University researcher will provide USF researchers with paper microscopes that will be used to test samples for helminth eggs. The USF researchers will share helminth samples with the Stanford researcher to use in the refinement of his paper microscope.
141	2016	Takeda	UBC	Takeda will provide a UBC researcher with a targeted set of compounds to screen against <i>M. tuberculosis</i> residing within macrophages.
142	2016	Takeda	UC San Diego	Takeda will provide a UC San Diego researcher with a targeted set of compounds to screen against <i>S. mansoni in vitro</i> . These screens will extend the researcher's earlier screening data to include a new chemical series targeting the same <i>S. mansoni</i> protein.
143	2017	Takeda	NIAID	Takeda and the NIAID/NIH will examine the feasibility of using Takeda's microneedle patch technology to administer a protein antigen-based, transmission-blocking malaria vaccine developed by the NIAID's Laboratory of Malaria Immunology and Vaccinology (LMIV). Under this agreement, Takeda and LMIV will confirm the compatibility of the vaccine antigen and microneedle

				patch8polymer. The NIAID scientists will subsequently evaluate the immunogenicity of the patch-administered vaccine <i>in vivo</i> .
144	2017	Takeda	UCSF	Takeda will provide a UCSF researcher with a set of preclinical/clinical-stage compounds to screen against <i>B. pahangi</i> .
145	2018	Takeda	SCRI	Takeda will provide SCRI investigators with selected anti-apoptotic Bcl-2 family inhibitors for anti-parasitic drug discovery including <i>P. falciparum</i> , <i>P. vivax</i> , <i>C. parvum</i> , <i>T. cruzi</i> , <i>Toxoplasma</i> , and <i>Leishmania spp.</i> The investigators will test inhibitors <i>in vitro</i> cell culture assays specific to each organism to identify candidates for further drug development. The next phase of this proposal will be to evaluate hit compounds in animal models.
146	2019	Takeda	IDRI	Takeda will provide an IDRI researcher with a set of MAP kinase inhibitors for screening for leishmaniasis drug discovery.
147	2014	UBC	McGill University	A UBC researcher will utilize his phage-display technology to develop new antibodies against Chagas disease host biomarkers identified by a McGill University researcher. Once developed, the antibody will be incorporated into the development of a diagnostic.
148	2014	UBC	Swiss TPH	A UBC researcher will provide a Swiss TPH researcher with avermectins that were promising against <i>M. tuberculosis</i> to screen against <i>M. ulcerans</i> .
149	2014	UBC	University of Buea	A UBC researcher will perform activity-guided fractionation on natural product extracts previously demonstrated by a University of Buea researcher to have anti-onchocercal activities.
150	2014	UBC	University of Ibadan	A UBC researcher will elucidate the structures of ~10 natural products previously demonstrated by a University of Ibadan researcher to have anti-malarial or anti-tuberculosis activities.
151	2015	UBC	University of Lagos	A UBC researcher will provide a University of Lagos researcher with an antibody against a human host protein. The University of Lagos researcher will use the antibody to examine the effect of reducing the level of the host protein on the severity of malaria.
152	2015	UBC	University of Lagos	A University of Lagos researcher will provide a UBC researcher with serum, plasma, and urine samples from patients with severe malaria and asymptomatic malaria, as well as samples from healthy controls. The UBC researcher will use proteomics to ascertain whether these samples have differing protein profiles, which could be used to identify biomarkers for a malaria diagnostic.
153	2015	UBC	WEHI	A WEHI researcher will provide a UBC researcher with recombinant <i>P. vivax</i> proteins involved in red blood cell entry. The UBC researcher will use his phage display technology to produce antibodies against the proteins that will be assessed for their ability to block <i>P. vivax</i> entry into red blood cells.
154	2018	UBC	University of Buea	An investigator at the University of Buea will share PCR products of two identified biomarker candidates to detect adult stage <i>O. volvulus</i> with a researcher at UBC. The UBC researcher will express and share the recombinant antigens to test for the antibody response with the goal of developing a point-of-care, antibody-based diagnostic device with the novel ability to detect adult stage <i>O. volvulus</i> .
155	2020	UBC	University of Ibadan	Dr. Chiaka Anumudu (U Ibadan) shared urine samples with Dr. Horacio Bach (UBC) to support validation of biomarkers and generation of recombinant antibodies to develop a serological test for fast diagnosis for schistosomiasis and bladder pathologies.
156	2015	UCSD	UW	A UC San Diego researcher will produce a set of <i>T. cruzi</i> antigens that a UW researcher will incorporate into a silicon chip-based Chagas disease diagnostic.
157	2020	UCSD	KNUST	A KNUST researcher will share their natural product extracts with a researcher at UCSD to screen for activity against HAT and schistosomiasis.
158	2021	UCSD	University of Zambia	The CDIPD at UCSD will test the antischistosomal activity of compounds synthesized and derived from natural sources by an investigator from University of Zambia to identify promising starting points for schistosomiasis drug discovery.
159	2014	UCSF	LSTM	An LSTM researcher will provide a UCSF researcher with stool and plasma samples from <i>Trichuris</i> -infected children from Ecuador. The UCSF researcher will compare the amount of specific factors present in infected vs. uninfected samples.
160	2014	UCSF	NIH	A UCSF researcher will provide an NIH researcher with an inhibitor that showed promise against schistosomes. The NIH researcher will screen the inhibitor against <i>Taenia cysticerci</i> – the causative agent of neurocysticercosis.
161	2014	UCSF	Stanford University	A UCSF researcher will test a Stanford University researcher's peptides against <i>Leishmania</i> parasites <i>in vitro</i> to determine the peptides' EC50s. Promising peptides will be selected for an electron microscopy assay.
162	2018	University of Buea	University of Melbourne	Investigators at the University Melbourne and Monash University identified compounds that inhibit the barber's pole worm, and were interested in screening them against other infectious worms. BVGH connected them with an investigator at University of Buea, who is developing inhibitors against <i>Onchocerca</i> . The University of Buea will screen the University of Melbourne compounds against <i>O. volvulus</i> to identify potential drug candidates.
163	2019	University of Dundee	KNUST	University of Dundee will provide a KNUST investigator with training in bioassay-guided fractionation of plant extracts to help advance the investigator's natural product anti-leishmanial drug discovery efforts.
164	2013	University of Lagos	Stanford University	A University of Lagos researcher will host two Stanford University researchers in order to test their paper microscope on field samples.
165	2014	University of Lagos	NIPD	A University of Lagos researcher will collaborate with an NIPD researcher to identify resistance to anti-malarial drugs using dry blood spots from Nigerian malaria patients treated with anti-malarials. The NIPD researcher will host a University of Lagos PhD student for two months. During this time, they will utilize the dried blood to monitor drug resistance markers in the malaria parasites contained within the samples.
166	2014	University of Lagos	Novartis	A University of Lagos researcher will provide Novartis with dry blood spots from malaria patients. Novartis will assess the feasibility of using dried blood spot sampling (DBSS) and next generation sequencing of <i>P. falciparum</i> in malaria patients in Nigeria.

167	2014	University of Lagos	Stanford University	A University of Lagos researcher will provide a Stanford University researcher with plasma and whole blood samples to compare efficacy of a malaria diagnostic. The Stanford University researcher will host a University of Lagos PhD student for 2-3 months.
168	2015	University of Lagos	McGill University	A University of Lagos researcher will provide a McGill University researcher with blood samples from malaria patients with varying levels of parasitemia. The McGill University researcher will use the blood to evaluate the sensitivity of a malaria diagnostic that he is developing.
169	2014	University of Mauritius	Northeastern University, Emory University	University of Mauritius, Northeastern University, and Emory University researchers will collaborate to assess the efficacy of tuberculosis drugs using different delivery strategies.
170	2014	USF	McMaster University	A McMaster University researcher will develop a filtration device capable of concentrating particulates from environmental samples. Once completed, a USF researcher will assess the device's ability to concentrate <i>Ascaris</i> eggs from soil and sewage samples.
171	2017	USF	University of Yaoundé I	A USF natural products chemist will isolate, characterize, and elucidate the structures of several fractions and pure compounds from Cameroonian fungi and medicinal plants. A University of Yaoundé I researcher previously demonstrated the promising effect of these products against <i>M. ulcerans</i> , <i>Leishmania</i> spp., <i>T. brucei</i> , <i>S. mansoni</i> , and <i>P. falciparum</i> . These products' characterizations are the first step towards their development as drugs.
172	2015	UW	NMIMR	A NMIMR researcher will collaborate with a researcher from UW to develop and implement a bioinformatics course for UW students. The course will examine single nucleotide polymorphisms in CYP genes, specifically comparing Caucasian vs. African vs. African American populations. The goal of the analysis is to ascertain which CYP polymorphisms are prevalent in West African and/or Ghanaian populations.
173	2019	University of Yaoundé I	GIBH	University of Yaoundé I will test the bactericidal activity of TB47 candidate provided by a GIBH investigator against clinical <i>M. ulcerans</i> strains to help advance the investigator's Buruli ulcer drug discovery efforts.
174	2015	WEHI	UCAD	A WEHI researcher will determine the sequence variation of a <i>P. falciparum</i> red blood cell-binding protein within a set of malaria patient samples provided by UCAD. The researchers will determine whether there is a correlation between the malaria patients' immune responses and the red blood cell-binding protein sequences.

60P 60 Degrees Pharmaceuticals
ABU Ahmadu Bello University
BRI Biomedical Research Institute
Caltech California Institute of Technology
CDC Centers for Disease Control and Prevention
CPC Centre Pasteur du Cameroun
CWHM Center for World Health & Medicine
DNDI Drugs for Neglected Diseases *initiative*
FIND Foundation for Innovative New Diagnostics
Fiocruz Oswaldo Cruz Foundation
GIBH Guangzhou Institute of Biomedicine and Health
GRIDD Griffith Institute for Drug Discovery, Griffith University
GSK GlaxoSmithKline
GWU The George Washington University
HAT Human African trypanosomiasis
IDRI Infectious Disease Research Institute
IP Institut Pasteur
J&J Johnson & Johnson
KEMRI Kenya Medical Research Institute

KCCR Kumasi Centre for Collaborative Research in Tropical Medicine
KNUST Kwame Nkrumah University of Science and Technology
KU University of Kansas
LNBio Brazilian Biosciences National Laboratory
LSTM Liverpool School of Tropical Medicine
MIT Massachusetts Institute of Technology
MMV Medicines for Malaria Venture
NIAID National Institute of Allergy and Infectious Diseases
NIH National Institutes of Health
NII National Institute of Immunology
NIMR Nigerian Institute of Medical Research
NMIMR Noguchi Memorial Institute for Medical Research
NIPD National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention
POC point-of-care
PHRI Public Health Research Institute
SAMRC South African Medical Research Council

SCRI Seattle Children's Research Institute
SSGID Seattle Structural Genomics Center for Infectious Disease
Swiss TPH Swiss Tropical and Public Health Institute
U of T University of Toronto
UBC University of British Columbia
UCB University of California, Berkeley
UCAD University Cheikh Anta Diop of Dakar
UC San Diego University of California, San Diego
UCSF University of California, San Francisco
UDUS Usmanu Danfodiyo University, Sokoto
USF University of South Florida
UTSW University of Texas Southwestern Medical Center
UVM University of Vermont
UW University of Washington
WEHI Walter and Eliza Hall Institute of Medical Research
WRAIR Walter Reed Army Institute of Research
WUSTL Washington University in St. Louis

* The business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics in the US and Canada.

**MSD is a trademark of Merck & Co., Inc., Kenilworth, NJ, USA